Cytek Biosciences, Inc.CTKBEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CTKB Q3 2025 Key Financial Metrics
Revenue
$52.3M
Gross Profit
$27.6M
Operating Profit
$-9.2M
Net Profit
$-5.5M
Gross Margin
52.7%
Operating Margin
-17.6%
Net Margin
-10.5%
YoY Growth
1.5%
Financial Flow
Cytek Biosciences, Inc. Q3 2025 Financial Summary
Cytek Biosciences, Inc. reported revenue of $52.3M for Q3 2025, with a net profit of $-5.5M (-10.5% margin). Cost of goods sold was $24.7M, operating expenses totaled $36.7M.
Key Financial Metrics
| Total Revenue | $52.3M |
|---|---|
| Net Profit | $-5.5M |
| Gross Margin | 52.7% |
| Operating Margin | -17.6% |
| Report Period | Q3 2025 |
Cytek Biosciences, Inc. Annual Revenue by Year
Cytek Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $200.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $200.5M |
| 2023 | $193.0M |
| 2022 | $164.0M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $58.2M | $44.9M | $46.6M | $51.5M | $57.5M | $41.5M | $45.6M | $52.3M |
| YoY Growth | 20.5% | 21.0% | -6.2% | 7.3% | -1.3% | -7.6% | -2.2% | 1.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $494.5M | $492.1M | $483.7M | $491.2M | $499.5M | $482.6M | $493.3M | $494.9M |
| Liabilities | $101.4M | $99.5M | $94.6M | $105.8M | $103.8M | $103.0M | $115.8M | $116.3M |
| Equity | $393.1M | $392.6M | $389.1M | $385.5M | $395.7M | $379.6M | $377.6M | $378.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $9.5M | $4.0M | $6.2M | $13.2M | $2.0M | $-125000 | $108000 | $-3.9M |